Delving into the Latest Updates on Centus Biotherapeutics Ltd. with Synapse

A RANDOMISED, PARALLEL, DOUBLE BLINDED STUDY TO COMPARE THE EFFICACY AND SAFETY OF FKB238 TO AVASTIN® IN 1ST LINE TREATMENT FOR PATIENTS WITH ADVANCED/RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN COMBINATION OF PACLITAXEL AND CARBOPLATIN

开始日期2017-01-01

申办/合作机构

Centus Biotherapeutics Ltd.

EUCTR2015-004104-33-DE / Not yet recruiting临床3期

A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients with Advanced/Recurrent Non Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin - AVANA

开始日期2016-09-13

申办/合作机构

Centus Biotherapeutics Ltd.

NCT02810457 / Completed临床3期

A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin

The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer

开始日期2016-09-07

申办/合作机构

Centus Biotherapeutics Ltd.

100 项与 Centus Biotherapeutics Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Centus Biotherapeutics Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Centus Biotherapeutics Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Centus Biotherapeutics Ltd. 相关的转化医学

登录后查看更多信息